Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

Efficacy and Safety Comparison of RAD001 Versus Sunitinib in the First-line and Second-line Treatment of Patients With Metastatic Renal Cell Carcinoma

ClinicalTrials.gov ID: NCT00903175

Public ClinicalTrials.gov record NCT00903175. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 6, 2026, 4:37 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

An Open-label, Multicenter Phase II Study to Compare the Efficacy and Safety of RAD001 as First-line Followed by Second-line Sunitinib Versus Sunitinib as First-line Followed by Second-line RAD001 in the Treatment of Patients With Metastatic Renal Cell Carcinoma.

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This study assessed the efficacy and safety of first-line RAD001 followed by second-line sunitinib versus the opposite sequence: first-line sunitinib followed by second-line RAD001 for the treatment of patients with MRCC.

Study identification

NCT ID
NCT00903175
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Novartis Pharmaceuticals
Industry
Enrollment
471 participants

Conditions and interventions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Sep 30, 2009
Primary completion
Apr 30, 2015
Completion
Apr 30, 2015
Last update posted
Nov 7, 2016

2009 – 2015

United States locations

U.S. sites
35
U.S. states
21
U.S. cities
34
Facility City State ZIP Site status
University of Alabama at Birmingham/ Kirklin Clinic Comprehensive CancerCenter (1) Birmingham Alabama 35294-0006
University of South Alabama / Mitchell Cancer Institute Dept. of Mitchell Cancer Inst. Mobile Alabama 36688
Highlands Oncology Group HighlandsOncGrp-Bentonville(2) Fayetteville Arkansas 72703
University of California San Diego - Moores Cancer Center Dept of Moores Cancer Ctr (5) La Jolla California 92093-0658
University of California at Los Angeles Dept. of UCLA (3) Los Angeles California 90095
University of Colorado Dept. of Anschutz Cancer (2) Aurora Colorado 80045
Norwalk Hospital Norwlak SC Norwalk Connecticut 06856
Georgetown University/Lombardi Cancer Center Dept.of Lombardi Cancer Ctr (2 Washington D.C. District of Columbia 20007-2197
Lynn Cancer Institute Boca Raton Florida 33486
University of Miami SC Miami Florida 33136
MD Anderson Cancer Center - Orlando Dept.ofMDACC-Orlando Orlando Florida 32806
University Cancer & Blood Center, LLC Dept of NE GCC (2) Athens Georgia 30607
Georgia Health Sciences University Dept. of MCG Augusta Georgia 30912
Summit Cancer Care Savannah Georgia 31405
NorthwesternUniv.Med.School/Robert H. Lurie Comp.Cancer Ctr Dept.ofNorthwesternMemHospital Chicago Illinois 60611
Loyola University Medical Center /Cardinal Bernardin Cancer Cardinal Bernardin Cancer (3) Maywood Illinois 60153
Crescent City Research Consortium, LLC SC Metairie Louisiana 70006
VA Maryland Health Care Dept.of GreenbaumCancerCent(7) Baltimore Maryland 21201
Weinberg Cancer Institute at Franklin Square Hospital Baltimore Maryland 21237-3998
Billings Clinic Dept of Billings Clinic(2) Billings Montana 59107
Hackensack University Medical Center DeptofHackensackUniv.MedCtr. Hackensack New Jersey 07601
Cooper Cancer Center Voorhees Township New Jersey 08043
Clinical Research Alliance Lake Success New York 11042
Memorial Sloan Kettering Cancer Center Dept. of MSKCC New York New York 10065
SUNY - Upstate Medical University Div. of Hematology-Oncology Syracuse New York 13210
University of North Carolina Dept. of LinbergerCancerCtr(3) Chapel Hill North Carolina 27599-7295
Levine Cancer Institute Oncology Charlotte North Carolina 28203
Duke University Medical Center Duke Durham North Carolina 27710
University of Oklahoma Health Sciences Center Dept of OHSC Oklahoma City Oklahoma 73104
St. Luke's Hospital and Health Network St Luke's Hospital (2) Bethlehem Pennsylvania 18015
The West Clinic Dept. of the West Clinic Memphis Tennessee 38120
The Center for Cancer and Blood Disorders Dept. of The Ctr for C & BD(2) Fort Worth Texas 76104
East Texas Medical Center Cancer Institute Tyler Texas 75701
Utah Cancer Specialists Dept.of Utah Cancer Spec. (3) Salt Lake City Utah 84106
Aurora Advanced Healthcare SC Milwaukee Wisconsin 53215

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 49 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00903175, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Nov 7, 2016 · Synced Sep 6, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00903175 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →